Physician profile
German Ernesto Crisol
NPI 1952333650
$6,053.74
in general payments reported to CMS, 2019-2025
23 companies · $852 in 2025
The $852 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $954 · 2021: $1,037 · 2022: $724 · 2023: $823 · 2024: $844 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,348.14 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals Lp | $1,033.82 | 2019-2025 | Farxiga |
| Amarin Pharma, INC. | $612.56 | 2019-2021 | |
| Novo Nordisk INC | $576.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $485.30 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $402.44 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $388.31 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.83 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $191.89 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $178.13 | 2019-2023 | |
| Lilly USA, LLC | $125.99 | 2020-2024 | Jardiance, Emgality, Mounjaro |
| Astellas Pharma US INC | $113.04 | 2019-2021 | |
| Hologic Sales and Service, LLC | $51.71 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $42.73 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.13 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $35.80 | 2019-2022 | |
| Mannkind Corporation | $33.52 | 2021 | |
| Abbvie INC. | $33.01 | 2022 | |
| Exact Sciences Corporation | $22.43 | 2025 | Cologuard Collection Kit |
| Cranial Technologies, INC | $14.67 | 2019 | |
| Optos, INC. | $14.25 | 2022 | |
| Sanofi Pasteur INC. | $12.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw German Crisol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.